Prognostic impact of concurrent radiographic progression at PSA-defined transition to castration resistance in de novo metastatic castration-sensitive prostate cancer

Background Radiographic progression (rPD) at castration-resistant prostate cancer (CRPC) diagnosis remains poorly characterized in real-world settings. We assessed its prognostic impact and the clinical features of patients with rPD in real-world de novo metastatic castration-sensitive prostate cancer (mCSPC). Methods We retrospectively analyzed 330 patients with de novo mCSPC who progressed to CRPC from two multi-institutional cohorts: a conventional androgen deprivation therapy or combined androgen blockade (ADT/CAB) cohort ( n = 272) and an upfront intensification cohort ( n = 58). At CRPC diagnosis, patients were categorized as having prostate-specific antigen (PSA)-only progression or PSA + rPD. Post-CRPC overall survival (OS) was evaluated using Kaplan–Meier and Cox proportional hazards models, while rPD-associated characteristics were examined using logistic regression. Results Across both cohorts, patients with PSA + rPD had significantly shorter post-CRPC OS than those with PSA-only progression (ADT/CAB: 21 vs. 44 months, P < 0.001; upfront: 14 vs. 24 months, P = 0.008). Univariate Cox regression confirmed the adverse prognostic impact of rPD (hazard ratios 2.25 [95% CI 1.53–3.29] and 2.49 [95% CI 1.22–5.07]). Lower baseline PSA was significantly associated with rPD in the upfront cohort (odds ratio [OR] 0.30, 95% CI 0.12–0.75, P = 0.010), with a non-significant trend in the ADT/CAB cohort (OR 0.71, 95% CI 0.47–1.06, P = 0.092). Conclusion Radiographic progression at CRPC transition predicts poor post-CRPC survival in real-world mCSPC patients, regardless of initial treatment. Lower baseline PSA may identify patients at increased risk of rPD, supporting careful radiographic monitoring at CRPC transition.

Authors

Publication Details

Journal
International Journal of Clinical Oncology
Published
2026-11-19
DOI
https://doi.org/10.1007/s10147-026-03239-0
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prognostic impact of concurrent radiographic progression at PSA-defined transition to castration resistance in de novo metastatic castration-sensitive prostate cancer

Koji Yoshimura, Noboru Shibasaki, Hiroaki Kawanishi, Takeru Fujimoto et al.
3 links
International Journal of Clinical Oncology
Prostate Cancer Treatment and Research
article

Prognostic impact of concurrent radiographic progression at PSA-defined transition to castration resistance in de novo metastatic castration-sensitive prostate cancer

Koji Yoshimura, Noboru Shibasaki, Hiroaki Kawanishi, Takeru Fujimoto, Masashi Kubota, Yu Miyazaki, Ryoma Kurahashi, Yoshiyuki Nagumo, Kei Mizuno, Kimihiko Masui, Shusuke Akamatsu, Takanari Kambe, Hiroshi Fujiwara, Takayuki Goto, Norihiko Masuda, Toshifumi Takahashi, Takashi Kobayashi, Takuro Miyagawa, Yuki Makino, Yuki Kita, Takayuki Sumiyoshi
article en

Abstract

Background Radiographic progression (rPD) at castration-resistant prostate cancer (CRPC) diagnosis remains poorly characterized in real-world settings. We assessed its prognostic impact and the clinical features of patients with rPD in real-world de novo metastatic castration-sensitive prostate cancer (mCSPC). Methods We retrospectively analyzed 330 patients with de novo mCSPC who progressed to CRPC from two multi-institutional cohorts: a conventional androgen deprivation therapy or combined androgen blockade (ADT/CAB) cohort ( n = 272) and an upfront intensification cohort ( n = 58). At CRPC diagnosis, patients were categorized as having prostate-specific antigen (PSA)-only progression or PSA + rPD. Post-CRPC overall survival (OS) was evaluated using Kaplan–Meier and Cox proportional hazards models, while rPD-associated characteristics were examined using logistic regression. Results Across both cohorts, patients with PSA + rPD had significantly shorter post-CRPC OS than those with PSA-only progression (ADT/CAB: 21 vs. 44 months, P < 0.001; upfront: 14 vs. 24 months, P = 0.008). Univariate Cox regression confirmed the adverse prognostic impact of rPD (hazard ratios 2.25 [95% CI 1.53–3.29] and 2.49 [95% CI 1.22–5.07]). Lower baseline PSA was significantly associated with rPD in the upfront cohort (odds ratio [OR] 0.30, 95% CI 0.12–0.75, P = 0.010), with a non-significant trend in the ADT/CAB cohort (OR 0.71, 95% CI 0.47–1.06, P = 0.092). Conclusion Radiographic progression at CRPC transition predicts poor post-CRPC survival in real-world mCSPC patients, regardless of initial treatment. Lower baseline PSA may identify patients at increased risk of rPD, supporting careful radiographic monitoring at CRPC transition.

International Journal of Clinical Oncology
Good health and well-being
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon